Eirgen Pharma

Eirgen Pharma is a research-driven company specializing in the development, manufacture, and supply of a broad range of High Potency Oral Solid Dose (OSD) Human & Veterinary specialty products. Since 2006, the company has been a pioneer in developing and manufacturing film-coated tablets, soft-gel capsules, and powder or liquid-filled hard-shell capsules, with a focus on successfully producing cancer chemotherapy drugs. This success has established strong partnerships with leading pharmaceutical companies, leading to the acquisition of Eirgen Pharma by the OPKO Health family of companies in 2015. The acquisition has empowered Eirgen Pharma to invest further in facilities and people, expanding their development and manufacturing capabilities. Currently, Eirgen Pharma serves patients in more than 60 countries worldwide, including major markets like the USA, Europe, Japan, Canada, Australia, the Middle East, and Africa. The company's centre of excellence in Waterford, Ireland, provides full turnkey CDMO services for the development, manufacture, and packaging of high potency oral dose medicines for both human and veterinary use. Eirgen Pharma also holds the production rights for numerous OSD products and has the capacity to manufacture each of these products at scale.